Selvax, founded in 1987, is focused on developing novel immunotherapy solutions with applications in both human and veterinary oncology
Growth was supported by stronger COVID vaccine sales and expanded government supply agreements in international markets
New facility at Pusa Road expands advanced diagnostic, theranostics, and treatment-planning capabilities across oncology, cardiology, neurology, and nephrology
Lifts full-year outlook as obesity drug boom accelerates
Under the terms, Arcellx shareholders received $115 per share in cash plus a non-transferable contingent value right
But acquisition charges drag earnings into loss
The association is intended to strengthen healthcare delivery standards, particularly in Oncology services, and enhance patient care outcomes
Our company remains focused on advancing monoclonal antibody therapeutics for solid tumors, with a clear emphasis on combination immunotherapy strategies
Collaboration to accelerate mRNA neoantigen therapy development for colorectal and pancreatic cancers using advanced immunology and dark genome insights
_256_384.png){kind=logo}
New plan integrates critical illness protection, market-linked health fund and preventive care platform for holistic financial and health security
Subscribe To Our Newsletter & Stay Updated
